SUMMIT Trial: Key Data for Bezuclastinib in Non-Advanced Systemic Mastocytosis

Lindsay Rein, MD, and Frederick Lansigan, MD, review key efficacy and safety data from the SUMMIT trial evaluating bezuclastinib (CGT9486) in patients with non-advanced systemic mastocytosis. They highlight improvements in symptom burden, mast cell activity, and relevant clinical endpoints. Rein and Lansigan discuss how these findings contribute to the growing evidence base supporting targeted KIT inhibition.